Baxter International (BAX)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$22.86+1.22%
Close 2026-07-07 · 1-day change
Reading BAX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BAX free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading BAX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BAX free→Baxter aims for adjusted EPS near $1.95 in 2026. Sales grew 3% in Q1. The company keeps paying a small dividend. It is expanding its operating system for better performance.
Baxter lost $15 million in Q1 2026. Earnings have been volatile with recent misses. Management changes may hurt execution. Growth is slow and profit margins are weak.
The price is about 33% below our fair value near $34. Analysts expect about 2% revenue growth. Our view sees risk in earnings and execution.
Breaks if: Dividend cut or suspension
Baxter plans to maintain its current quarterly dividend of $0.01 per share.
Stated in 2 of last 2 quarters. Baxter declared a quarterly dividend of $0.01 per share. Despite maintaining this dividend, net income was negative $15 million in 2026-Q1, indicating financial strain.
Breaks if: Adjusted EPS falls below $1.85 in FY26
Baxter continues to emphasize its commitment to achieving its full-year 2026 financial targets.
Stated in 4 of last 4 quarters. Baxter reiterated its full-year 2026 financial outlook, including adjusted EPS of $1.85 to $2.05. Revenue for 2026-Q1 was $2.7 billion, a 3% increase on a reported basis. Despite the reiterated outlook, the financials show limited progress with a net income loss of $15 million in 2026-Q1.
Breaks if: Significant management departures or failures reported
Breaks if: Revenue growth falls below 2% YoY next year
Baxter continues to emphasize its commitment to achieving its full-year 2026 financial targets.
Stated in 4 of last 4 quarters. Baxter reiterated its full-year 2026 financial outlook, including adjusted EPS of $1.85 to $2.05. Revenue for 2026-Q1 was $2.7 billion, a 3% increase on a reported basis. Despite the reiterated outlook, the financials show limited progress with a net income loss of $15 million in 2026-Q1.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Expect to maintain current quarterly dividend of $0.01/share.”
“Declared a quarterly cash dividend of $0.01 per share.”
“Reiterates full-year 2026 financial outlook.”
“Reiterated its full-year 2026 financial outlook.”
“Reiterated full-year 2026 financial outlook.”
“Reiterated full-year 2026 financial outlook.”
“Reiterates full-year 2026 financial outlook.”
“Reiterated its full-year 2026 financial outlook.”
“Reiterated full-year 2026 financial outlook.”
“Reiterated full-year 2026 financial outlook.”
Baxter is expanding its GPS as the enterprise operating system for continuous improvement.